Loading...
ZY logo

Zymergen Inc.NasdaqGS:ZY Aktienübersicht

Marktkapitalisierung US$253.6m
Aktienkurs
n/a
Mein Marktwert
n/v
1Y-76.7%
7D3.4%
1D
Wert des Portfolios
​
Siehe

Zymergen Inc.

NasdaqGS:ZY Lagerbericht

Marktkapitalisierung: US$253.6m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Zymergen (ZY) Aktienübersicht

Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. Mehr Details

ZY grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung0/6
Künftiges Wachstum0/6
Vergangene Leistung0/6
Finanzielle Gesundheit4/6
Dividenden0/6

Risikoanalyse

Hat weniger als 1 Jahr Cash Runway

Die Einnahmen sind im vergangenen Jahr um 22.1% zurückgegangen.

Volatiler Aktienkurs in den letzten 3 Monaten im Vergleich zum US -Markt

Signifikante Insiderverkäufe in den letzten 3 Monaten


ZY Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Zymergen Inc. Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Zymergen
Historische Aktienkurse
Aktueller AktienkursUS$2.43
52-Wochen-HochUS$11.87
52-Wochen-TiefUS$1.10
Beta0
1 Monat Veränderung-6.90%
3 Monate Veränderung21.50%
1 Jahr Veränderung-76.75%
3 Jahre Veränderungn/a
5 Jahre Veränderungn/a
Veränderung seit IPO-93.55%

Aktuelle Nachrichten und Updates

Seeking Alpha • Aug 25

Zymergen chief scientific officer to depart as company lays off more employees

Zach Serber, chief scientific officer of Zymergen (NASDAQ:ZY) and a co-founder, is leaving the company on Sept. 22. Zymergen (ZY) also said it is laying off another 80 employees. This follows the termination of 80 employees in late July. The company's shares are down 63% year to date. Seeking Alpha's Quant Rating views Zymergen (ZY) as a hold.
Seeking Alpha • Jul 26

Zymergen: Ginkgo Bioworks Acquisition

An acquisition was probably the only viable option for Zymergen, but shareholders are likely to be disappointed by the price, given the company’s ambitions at the IPO. The deal makes sense for Ginkgo as it reduces competition and expands its capabilities at a minimal cost. An all-stock transaction gives Zymergen shareholders exposure to a company with much brighter prospects, but there is a significant downside risk if Ginkgo stumbles in the future. Ginkgo Bioworks (DNA) has entered into an agreement to acquire Zymergen (ZY). While Zymergen shareholders are unlikely to be thrilled by the price, the company's financial position gave them little option. Ginkgo continues to solidify their position as the leading synbio platform, but is richly valued based on current operating metrics. The all-stock deal gives Zymergen shareholders exposure to a company with better prospects, but also introduces valuation risk. Zymergen At the time of Zymergen's IPO, the company appeared to be reaching an inflection point, with multiple products nearing commercialization. Zymergen's narrative and valuation fell apart soon after though, when the company announced these products were not viable and that the CEO would be stepping down. Since then, Zymergen has been in a race to restructure costs and create revenue streams, in the hope of staving off bankruptcy. Given the company's cost structure, balance sheet and the state of equity markets, an acquisition was probably the best hope for shareholders. Figure 1: Zymergen Target Opportunities (source: Zymergen) Automation & Tech Platform Zymergen had been in the process of offering modular automation systems to the market, to commercialize their lab expertise. In particular, Octant had purchased 11 of Zymergen's Reconfigurable Automation Carts (RACs) to help scale their drug discovery platform. These RACs are designed to improve the throughput, efficiency, and reliability of lab operations and are controlled by Zymergen's cloud software. Zymergen previously stated that they had approximately 30 prospects, with a typical 10-RAC system costing between 1-2.5 million USD and requiring approximately 400,000 USD in annual software and support costs. Figure 2: Zymergen RAC (source: Zymergen) Advanced Materials Zymergen have been developing materials, which they have bracketed under agriculture, water repellency, advanced polymers and enzymes. Zymergen has a fairly mature nitrogen fixation program that uses engineered microbes to replace nitrogen fertilizers. In their water repellency program, Zymergen have been exploring coated straws and recently demonstrated the successful conversion of their coated paper into an end product manufactured on a potential customer's production line. Within advanced polymers, Zymergen has announced a supply agreement with 3D4Makers to provide Polyimide for use in 3D printing. Polyimide is a high-strength polymer that is flame retardant, has excellent insulating properties and excellent thermal stability. The polymer will be offered to 3D4Maker's customers for applications like aerospace, automotive, and transportation. Zymergen has also developed mRNA enzymes (VCE and 2'-O-MT) for use in vaccines. Drug Discovery Zymergen is leveraging their metagenomic database to uncover natural molecules that inhibit targets of interest, with an initial focus on oncology. There are millions of novel bioactives from uncultured bacteria and fungi and Zymergen are computationally predicting the activity of these bioactives against human targets. Figure 3: Therapeutic Classes and Potential Targets (source: Zymergen) Ginkgo Acquisition Ginkgo is acquiring Zymergen in an all-stock transaction that values Zymergen at approximately a 300 million USD market capitalization. The stated aim of the acquisition is to accelerate the development of Ginkgo's platform. Ginkgo plan to integrate Zymergen's automation, software, data science tools and biological assets. Zymergen's core technical team will be retained, which will help Ginkgo to fulfill their hiring plans. Strategic alternatives will be considered for Zymergen's Advanced Materials and Drug Discovery businesses. It is possible that these will be spun out and become Ginkgo customers, in a similar manner to companies like Joyn Bio and Motif Food Works. Ginkgo has been active in M&A in recent years, with acquisitions either building on the capabilities of their Foundries, or providing the necessary vertical expertise to attract customers and successfully bring products to market. Figure 4: Ginkgo Acquisitions (source: Ginkgo Bioworks) Ginkgo is doing the right thing by conducting countercyclical M&A, but it is unclear how much value Zymergen will add. Ginkgo's appeal should be that they have singular capabilities, and acquiring competing synbio companies for their technology undermines this. Jason Kelly stated that approximately 70% of the deal's value lies in Zymergen's physical assets (foundry / automation). There could be significant issues integrating these assets into Ginkgo's workflows, although Zymergen's successful rollout of automation solutions at Octant has given Ginkgo confidence that this can be managed. Figure 5: Ginkgo's Plan for Zymergen's Assets (source: Ginkgo Bioworks) In its current state, Zymergen would significantly weaken Ginkgo's financial position, and hence it is likely that there will be a large reduction in headcount. Zymergen had approximately 500 employees at the end of 2021 in comparison to Ginkgo's 640 employees, but is not currently generating any meaningful revenue.
Seeking Alpha • Jul 14

Zymergen expands agreement with Octant on developing breakthrough medicines

Biotech company Zymergen (NASDAQ:ZY) expanded an agreement with therapeutics company Octant in relation to developing breakthrough medicines. Octant has more than doubled its initial investment through the purchase of six additional Reconfigurable Automation Carts, or RAC, units. ZY shares were trading +2.15% post-market. Source: Press Release

Recent updates

Seeking Alpha • Aug 25

Zymergen chief scientific officer to depart as company lays off more employees

Zach Serber, chief scientific officer of Zymergen (NASDAQ:ZY) and a co-founder, is leaving the company on Sept. 22. Zymergen (ZY) also said it is laying off another 80 employees. This follows the termination of 80 employees in late July. The company's shares are down 63% year to date. Seeking Alpha's Quant Rating views Zymergen (ZY) as a hold.
Seeking Alpha • Jul 26

Zymergen: Ginkgo Bioworks Acquisition

An acquisition was probably the only viable option for Zymergen, but shareholders are likely to be disappointed by the price, given the company’s ambitions at the IPO. The deal makes sense for Ginkgo as it reduces competition and expands its capabilities at a minimal cost. An all-stock transaction gives Zymergen shareholders exposure to a company with much brighter prospects, but there is a significant downside risk if Ginkgo stumbles in the future. Ginkgo Bioworks (DNA) has entered into an agreement to acquire Zymergen (ZY). While Zymergen shareholders are unlikely to be thrilled by the price, the company's financial position gave them little option. Ginkgo continues to solidify their position as the leading synbio platform, but is richly valued based on current operating metrics. The all-stock deal gives Zymergen shareholders exposure to a company with better prospects, but also introduces valuation risk. Zymergen At the time of Zymergen's IPO, the company appeared to be reaching an inflection point, with multiple products nearing commercialization. Zymergen's narrative and valuation fell apart soon after though, when the company announced these products were not viable and that the CEO would be stepping down. Since then, Zymergen has been in a race to restructure costs and create revenue streams, in the hope of staving off bankruptcy. Given the company's cost structure, balance sheet and the state of equity markets, an acquisition was probably the best hope for shareholders. Figure 1: Zymergen Target Opportunities (source: Zymergen) Automation & Tech Platform Zymergen had been in the process of offering modular automation systems to the market, to commercialize their lab expertise. In particular, Octant had purchased 11 of Zymergen's Reconfigurable Automation Carts (RACs) to help scale their drug discovery platform. These RACs are designed to improve the throughput, efficiency, and reliability of lab operations and are controlled by Zymergen's cloud software. Zymergen previously stated that they had approximately 30 prospects, with a typical 10-RAC system costing between 1-2.5 million USD and requiring approximately 400,000 USD in annual software and support costs. Figure 2: Zymergen RAC (source: Zymergen) Advanced Materials Zymergen have been developing materials, which they have bracketed under agriculture, water repellency, advanced polymers and enzymes. Zymergen has a fairly mature nitrogen fixation program that uses engineered microbes to replace nitrogen fertilizers. In their water repellency program, Zymergen have been exploring coated straws and recently demonstrated the successful conversion of their coated paper into an end product manufactured on a potential customer's production line. Within advanced polymers, Zymergen has announced a supply agreement with 3D4Makers to provide Polyimide for use in 3D printing. Polyimide is a high-strength polymer that is flame retardant, has excellent insulating properties and excellent thermal stability. The polymer will be offered to 3D4Maker's customers for applications like aerospace, automotive, and transportation. Zymergen has also developed mRNA enzymes (VCE and 2'-O-MT) for use in vaccines. Drug Discovery Zymergen is leveraging their metagenomic database to uncover natural molecules that inhibit targets of interest, with an initial focus on oncology. There are millions of novel bioactives from uncultured bacteria and fungi and Zymergen are computationally predicting the activity of these bioactives against human targets. Figure 3: Therapeutic Classes and Potential Targets (source: Zymergen) Ginkgo Acquisition Ginkgo is acquiring Zymergen in an all-stock transaction that values Zymergen at approximately a 300 million USD market capitalization. The stated aim of the acquisition is to accelerate the development of Ginkgo's platform. Ginkgo plan to integrate Zymergen's automation, software, data science tools and biological assets. Zymergen's core technical team will be retained, which will help Ginkgo to fulfill their hiring plans. Strategic alternatives will be considered for Zymergen's Advanced Materials and Drug Discovery businesses. It is possible that these will be spun out and become Ginkgo customers, in a similar manner to companies like Joyn Bio and Motif Food Works. Ginkgo has been active in M&A in recent years, with acquisitions either building on the capabilities of their Foundries, or providing the necessary vertical expertise to attract customers and successfully bring products to market. Figure 4: Ginkgo Acquisitions (source: Ginkgo Bioworks) Ginkgo is doing the right thing by conducting countercyclical M&A, but it is unclear how much value Zymergen will add. Ginkgo's appeal should be that they have singular capabilities, and acquiring competing synbio companies for their technology undermines this. Jason Kelly stated that approximately 70% of the deal's value lies in Zymergen's physical assets (foundry / automation). There could be significant issues integrating these assets into Ginkgo's workflows, although Zymergen's successful rollout of automation solutions at Octant has given Ginkgo confidence that this can be managed. Figure 5: Ginkgo's Plan for Zymergen's Assets (source: Ginkgo Bioworks) In its current state, Zymergen would significantly weaken Ginkgo's financial position, and hence it is likely that there will be a large reduction in headcount. Zymergen had approximately 500 employees at the end of 2021 in comparison to Ginkgo's 640 employees, but is not currently generating any meaningful revenue.
Seeking Alpha • Jul 14

Zymergen expands agreement with Octant on developing breakthrough medicines

Biotech company Zymergen (NASDAQ:ZY) expanded an agreement with therapeutics company Octant in relation to developing breakthrough medicines. Octant has more than doubled its initial investment through the purchase of six additional Reconfigurable Automation Carts, or RAC, units. ZY shares were trading +2.15% post-market. Source: Press Release
Seeking Alpha • Jun 03

Zymergen Seeks Turnaround But Runway Is Running Low

Zymergen went public in April 2021, raising around $500 million in an IPO. The firm designs advanced materials technologies to improve manufacturing processes. ZY has been decimated by the market after no revenue in 2021/2022 and the sudden departure of its CEO. While the firm has been restructured, it only has one year of cash runway, which isn't much for a zero revenue and high operating loss company.
Seeking Alpha • May 23

Zymergen: A Humbled Company With A Business On The Ropes

The stock for Zymergen Inc. has been in freefall since an initial recovery attempt following last year's disaster. The company will run out of cash in 2023 and prospects for viability remain murky. Of the many research and development projects underway, reconfigurable automation carts offer the most likely foundation for earning an 11th-hour infusion of cash. The coming full-time CEO will have to hit the ground running with a major sense of urgency to pull Zymergen off the ropes.
Analyseartikel • Mar 27

Some Zymergen Inc. (NASDAQ:ZY) Analysts Just Made A Major Cut To Next Year's Estimates

Today is shaping up negative for Zymergen Inc. ( NASDAQ:ZY ) shareholders, with the analysts delivering a substantial...
Analyseartikel • Mar 25

Zymergen Inc. (NASDAQ:ZY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Zymergen Inc. ( NASDAQ:ZY ) missed earnings with its latest full-year results, disappointing overly-optimistic...
Seeking Alpha • Dec 09

Zymergen: Total Chaos

Rather than achieving a growth inflection point, Zymergen recently abandoned their most mature products and rationalized their product portfolio. The CEO has been replaced and the co-founder and operations chief has stepped down, along with a hiring freeze and a large headcount reduction, all of which point towards problems. Zymergen no longer has a clear path to profitability, which raises questions about the company as an ongoing concern.
Seeking Alpha • Aug 05

Zymergen: How To Buy A Disaster

Shares in Biofacturing company Zymergen (ZY) collapsed in epic fashion after a catastrophic setback in its commercialization plans. The stock is now significantly de-risked and worthy of speculation. I am considering a bet on the company's cash position, new management, and promising technology.
Analyseartikel • Aug 05

Analysts Just Made A Major Revision To Their Zymergen Inc. (NASDAQ:ZY) Revenue Forecasts

Market forces rained on the parade of Zymergen Inc. ( NASDAQ:ZY ) shareholders today, when the analysts downgraded...

Aktionärsrenditen

ZYUS ChemicalsUS Markt
7D3.4%0.1%1.1%
1Y-76.7%8.9%28.7%

Rendite im Vergleich zur Industrie: ZY unter dem Niveau der Branche US Chemicals , die im vergangenen Jahr eine Rendite von 8.9% erzielte.

Rendite vs. Markt: ZY hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 28.7 erzielte.

Preisvolatilität

Is ZY's price volatile compared to industry and market?
ZY volatility
ZY Average Weekly Movement13.3%
Chemicals Industry Average Movement7.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stabiler Aktienkurs: Der Aktienkurs von ZY war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.

Volatilität im Zeitverlauf: ZYDie wöchentliche Volatilität (13%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.

Über das Unternehmen

GegründetMitarbeiterCEOWebsite
2013505n/awww.zymergen.com

Zymergen Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Zymergen im Vergleich zum Marktanteil des Unternehmens?
ZY grundlegende Statistiken
MarktanteilUS$253.58m
Gewinn(TTM)-US$364.92m
Umsatz(TTM)US$14.58m
17.4x
Kurs-Umsatz-Verhältnis
-0.7x
Kurs-Gewinn-Verhältnis

Ist ZY zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ZY Gewinn- und Verlustrechnung (TTM)
EinnahmenUS$14.58m
Kosten der EinnahmenUS$178.03m
Bruttogewinn-US$163.45m
Sonstige AusgabenUS$201.47m
Gewinn-US$364.92m

Zuletzt gemeldete Gewinne

Jun 30, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)-3.50
Bruttomarge-1,121.15%
Nettogewinnspanne-2,503.04%
Schulden/Eigenkapital-Verhältnis0%

Wie hat sich ZY auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2022/10/23 19:51
Aktienkurs zum Tagesende2022/10/18 00:00
Gewinne2022/06/30
Jährliche Einnahmen2021/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Zymergen Inc. wird von 5 Analysten beobachtet. dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Derik de BruinBofA Global Research
Matthew SykesGoldman Sachs
Sriharsha PappuHSBC